Market revenue in 2023 | USD 0.3 million |
Market revenue in 2030 | USD 4.4 million |
Growth rate | 46.5% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Japan live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is considered one of the largest biopharmaceutical markets across the globe. The growing biopharmaceutical industry and increasing demand for CDMOs in Japan are contributing to the growth of live biotherapeutic and microbiome products.
In Japan, there has been a significant increase in the overall number of clinical trials on emerging live biotherapeutics and microbiomes as the government is undertaking steps to offer regulatory support & promote clinical trials in the country. These factors are expected to boost the market over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account